Articles with keyword pd-1

• Neoadjuvant anti PD-1 / PD-L1 immune checkpoint inhibitors in locall y advanced gastric cancer with microsatellite insta bility

  A.Y. Navmatulya, V.A. Chubenko, S.A. Savchuk, F.R. Almukhametova, P.Y. Tsuprun, A.I. Kuznetsov, G.S. Inusilaev, V.A. Heinstein, K.V. Shelekhova, Е.М. Zykov, B.I. Miroshnikov, V.M. Moiseenko

  Gastric cancer, immune checkpoint inhibitors, MSI, microsatellite instability, PD-1, PD-L1, objective response, pathologic response.

• Immune checkpoint inhibitors in the treatment of cervical cancer: literature review

  O.A. Pardabekova

  cervical cancer, immunotherapy, immune checkpoint inhibitors, pd-1,

• Immuno-related adverse events of checkpoint inhibitors

  G.Yu. Kharkevich, K.V. Orlova

  immune-related adverse events, skin toxicity, colitis, hepatitis,anti-CTLA-4, anti-PD-1, hypophysitis, melanoma

• Biomarkers predicting the effect of immunotherapy: what you need to know in practice?

  A.M. Konstantinova

  immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.

• Efficacy of immune checkpoints inhibitors in the treatment of solid tumors

  A.A. Rumyantsev, S.A. Tjulandin

  drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy